Bank of America
VNDA icon

Bank of America’s Vanda Pharmaceuticals VNDA Stock Holding History

Bank of America’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8,500
Closed -$136K – 7255
2016
Q4 		$136K Hold
8,500
– – ﹤0.01% 5489
2016
Q3 		$141K Hold
8,500
– – ﹤0.01% 5284
2016
Q2 		$95K Buy
+8,500
New +$82.3K ﹤0.01% 5549
2015
Q2 		– Sell
-55,000
Closed -$512K – 7419
2015
Q1 		$512K Buy
55,000
+52,300
+1,937% +$591K ﹤0.01% 4303
2014
Q4 		$39K Sell
2,700
-500
-16% -$5.92K ﹤0.01% 6479
2014
Q3 		$33K Buy
3,200
+700
+28% +$9.18K ﹤0.01% 6787
2014
Q2 		$40K Sell
2,500
-5,400
-68% -$71.9K ﹤0.01% 6810
2014
Q1 		$128K Buy
7,900
+6,300
+394% +$89.6K ﹤0.01% 5779
2013
Q4 		$20K Sell
1,600
-2,500
-61% -$25.1K ﹤0.01% 7031
2013
Q3 		$45K Sell
4,100
-13,100
-76% -$140K ﹤0.01% 6491
2013
Q2 		$139K Buy
+17,200
New +$116K ﹤0.01% 5936

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's VNDA Position: Q1 2026 in Review

Bank of America increased its Vanda Pharmaceuticals (VNDA) stake by 136% in Q1 2026, buying an estimated $852K and bringing the position to 191,927 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4356.

Bank of America first reported a position in VNDA in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.4M in Q1 2019. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Bank of America held 191,927 shares of Vanda Pharmaceuticals worth $1.33M as of Q1 2026.
  • Bank of America bought 110,513 Vanda Pharmaceuticals shares in Q1 2026, an estimated $852K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4356 holding.
  • Bank of America first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Vanda Pharmaceuticals position peaked at $11.4M in Q1 2019.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.